204 related articles for article (PubMed ID: 16778472)
1. [Nonsteroidal anti-inflammatory agents--choice between disturbances of gastrointestinal tract and cardiovascular toxicity].
Gumbrevicius G; Milasius A; Sveikata A
Medicina (Kaunas); 2006; 42(5):429-39. PubMed ID: 16778472
[TBL] [Abstract][Full Text] [Related]
2. Selective COX-2 inhibitors: a promise unfulfilled?
Henry D; McGettigan P
Gastroenterology; 2007 Feb; 132(2):790-4. PubMed ID: 17261306
[No Abstract] [Full Text] [Related]
3. [NSAID therapy. Gastrointestinal risks of classic NSAID are underestimated].
MMW Fortschr Med; 2010 May; 152(20):46-7. PubMed ID: 20552882
[No Abstract] [Full Text] [Related]
4. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
Moore RA; Derry S; McQuay HJ
BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
[TBL] [Abstract][Full Text] [Related]
5. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.
García Rodríguez LA; Barreales Tolosa L
Gastroenterology; 2007 Feb; 132(2):498-506. PubMed ID: 17258728
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
[TBL] [Abstract][Full Text] [Related]
7. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
Limmer S; Ittel TH; Wietholtz H
Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
[TBL] [Abstract][Full Text] [Related]
8. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
9. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
10. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal Antiinflammatory Drugs, Anticoagulation, and Upper Gastrointestinal Bleeding.
Lee MW; Katz PO
Clin Geriatr Med; 2021 Feb; 37(1):31-42. PubMed ID: 33213773
[TBL] [Abstract][Full Text] [Related]
12. [Antiplatelet drugs and gastrointestinal bleeding: numquam periclum sine periclo vincitur].
Rossini R; Lucà MG; Scuri P; Invernizzi P; Strazzabosco M; Gavazzi A
Ital Heart J Suppl; 2005 Oct; 6(10):621-6. PubMed ID: 16273749
[No Abstract] [Full Text] [Related]
13. [NSAIDs and COX-2-inhibitors: current status].
Kneitz C; Tony HP; Krüger K
Internist (Berl); 2006 May; 47(5):533-4, 536-8, 540. PubMed ID: 16557412
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
15. [Pathogen eradication prevents gastrointestinal complications].
MMW Fortschr Med; 2007 Oct; 149(43):58-9. PubMed ID: 17992910
[No Abstract] [Full Text] [Related]
16. [Safety of selective cyclooxygenase-2 inhibitors taken for a long time].
Lamarque D
Bull Cancer; 2004 May; 91 Suppl 2():S117-24. PubMed ID: 15899636
[TBL] [Abstract][Full Text] [Related]
17. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
[TBL] [Abstract][Full Text] [Related]
18. [Coronary risks with NSAID and coxibs. The end of hysteria].
Einecke D
MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
[No Abstract] [Full Text] [Related]
19. [Safe prescription recommendations for non steroidal anti-inflammatory drugs: Consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)].
Lanas A; Benito P; Alonso J; Hernández-Cruz B; Barón-Esquivias G; Perez-Aísa A; Calvet X; García-Llorente JF; Gobbo M; Gonzalez-Juanatey JR
Gastroenterol Hepatol; 2014 Mar; 37(3):107-27. PubMed ID: 24529572
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroids and peptic ulceration.
Ellershaw JE; Kelly MJ
Palliat Med; 1994 Oct; 8(4):313-9. PubMed ID: 7812482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
